company background image

Chong Kun Dang Holdings KOSE:A001630 Stock Report

Last Price


Market Cap







24 Sep, 2022


Company Financials
A001630 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance1/6
Financial Health3/6

A001630 Stock Overview

Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally.

Chong Kun Dang Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Chong Kun Dang Holdings
Historical stock prices
Current Share Price₩53,900.00
52 Week High₩91,900.00
52 Week Low₩53,800.00
1 Month Change-9.87%
3 Month Change-4.43%
1 Year Change-39.17%
3 Year Change-41.98%
5 Year Change-22.89%
Change since IPO75.68%

Recent News & Updates

Apr 28
Here's Why Chong Kun Dang Holdings (KRX:001630) Has A Meaningful Debt Burden

Here's Why Chong Kun Dang Holdings (KRX:001630) Has A Meaningful Debt Burden

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Apr 08
Could Chong Kun Dang Holdings Corp. (KRX:001630) Have The Makings Of Another Dividend Aristocrat?

Could Chong Kun Dang Holdings Corp. (KRX:001630) Have The Makings Of Another Dividend Aristocrat?

Dividend paying stocks like Chong Kun Dang Holdings Corp. ( KRX:001630 ) tend to be popular with investors, and for...

Shareholder Returns

A001630KR PharmaceuticalsKR Market

Return vs Industry: A001630 matched the KR Pharmaceuticals industry which returned -38.9% over the past year.

Return vs Market: A001630 underperformed the KR Market which returned -27.4% over the past year.

Price Volatility

Is A001630's price volatile compared to industry and market?
A001630 volatility
A001630 Average Weekly Movement2.3%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement5.6%
10% most volatile stocks in KR Market10.5%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A001630 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: A001630's weekly volatility (2%) has been stable over the past year.

About the Company

194140Tae Young Kim

Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Chong Kun Dang Holdings Fundamentals Summary

How do Chong Kun Dang Holdings's earnings and revenue compare to its market cap?
A001630 fundamental statistics
Market Cap₩263.91b
Earnings (TTM)₩2.30b
Revenue (TTM)₩906.92b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A001630 income statement (TTM)
Cost of Revenue₩495.07b
Gross Profit₩411.85b
Other Expenses₩409.55b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)468.82
Gross Margin45.41%
Net Profit Margin0.25%
Debt/Equity Ratio48.0%

How did A001630 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is A001630 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A001630?

Other financial metrics that can be useful for relative valuation.

A001630 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA22x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does A001630's PE Ratio compare to its peers?

A001630 PE Ratio vs Peers
The above table shows the PE ratio for A001630 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average22.3x
A016580 Whan In PharmLtd
A009290 Kwang Dong Pharmaceutical
A003220 Daewon Pharmaceutical
A216080 JETEMA
A001630 Chong Kun Dang Holdings

Price-To-Earnings vs Peers: A001630 is expensive based on its Price-To-Earnings Ratio (115x) compared to the peer average (22.3x).

Price to Earnings Ratio vs Industry

How does A001630's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

Price-To-Earnings vs Industry: A001630 is expensive based on its Price-To-Earnings Ratio (115x) compared to the KR Pharmaceuticals industry average (20.1x)

Price to Earnings Ratio vs Fair Ratio

What is A001630's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A001630 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio115x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A001630's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of A001630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A001630 (₩53900) is trading above our estimate of fair value (₩36997.89)

Significantly Below Fair Value: A001630 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Chong Kun Dang Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chong Kun Dang Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of A001630’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Chong Kun Dang Holdings performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A001630 has high quality earnings.

Growing Profit Margin: A001630's current net profit margins (0.3%) are lower than last year (6.7%).

Past Earnings Growth Analysis

Earnings Trend: A001630's earnings have declined by 3.6% per year over the past 5 years.

Accelerating Growth: A001630's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A001630 had negative earnings growth (-96.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4%).

Return on Equity

High ROE: A001630's Return on Equity (-0.7%) is considered low.

Discover strong past performing companies

Financial Health

How is Chong Kun Dang Holdings's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A001630's short term assets (₩426.4B) exceed its short term liabilities (₩354.6B).

Long Term Liabilities: A001630's short term assets (₩426.4B) exceed its long term liabilities (₩206.3B).

Debt to Equity History and Analysis

Debt Level: A001630's net debt to equity ratio (31.5%) is considered satisfactory.

Reducing Debt: A001630's debt to equity ratio has increased from 12.2% to 48% over the past 5 years.

Debt Coverage: A001630's debt is not well covered by operating cash flow (11.6%).

Interest Coverage: Insufficient data to determine if A001630's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies


What is Chong Kun Dang Holdings's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A001630's dividend (2.6%) is higher than the bottom 25% of dividend payers in the KR market (1.02%).

High Dividend: A001630's dividend (2.6%) is low compared to the top 25% of dividend payers in the KR market (3.26%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, A001630 has been paying a dividend for less than 10 years.

Growing Dividend: A001630's dividend payments have increased, but the company has only paid a dividend for 3 years.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (301.9%), A001630's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: A001630 is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Tae Young Kim

no data



Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 9 shareholders own 51.74% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Jang-Han Lee
2,348,106₩126.6b0.04%no data
The Vanguard Group, Inc.
91,919₩5.0b0%no data
Dimensional Fund Advisors LP
49,966₩2.7b0.35%no data
Mackenzie Financial Corporation
29,316₩1.6b0%no data
AXA Investment Managers S.A.
5,805₩312.9m0%no data
Charles Schwab Investment Management, Inc.
5,564₩299.9m0%no data
Thrivent Investment Management, Inc.
1,844₩99.4m0%no data
Goldman Sachs Asset Management, L.P.
738₩39.8m0%no data
American Century Investment Management Inc
154₩8.3m-51.42%no data

Company Information

Chong Kun Dang Holdings Corp.'s employee growth, exchange listings and data sources

Key Information

  • Name: Chong Kun Dang Holdings Corp.
  • Ticker: A001630
  • Exchange: KOSE
  • Founded: 1941
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩263.912b
  • Shares outstanding: 4.90m
  • Website:

Number of Employees


  • Chong Kun Dang Holdings Corp.
  • 8, Chungjeong-ro
  • Seodaemun-gu
  • Seoul
  • South Korea


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A001630KOSE (Korea Stock Exchange)YesCommon StockKRKRWJan 1992

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.